Has Nathaniel Jones, MD received payments from drug or device companies?

Yes. Drug and device makers reported $528,842 in general payments to Nathaniel Jones, MD across 333 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Nathaniel Jones, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Nathaniel Jones, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Nathaniel Jones, MD

Gynecologic Oncology · Mobile, ALNPI 1255645594

Payments from drug & device makers

$528,842in general payments, 2019–2025

Across 333 payments — averaging $1588.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$501K
Intuitive Surgical$17K
Organon$3K
Seagen Inc.$2K
Johnson & Johnson$480
Daiichi Sankyo Inc.$478
plus $4K from 45 others

What the payments were for

Consulting fees$1,9258%
Travel & lodging$2,73711%
Food & beverage$7,75932%
Education$12,11149%
Gifts$490%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	35	$501,342
Intuitive Surgical	29	$17,074
Organon	2	$3,250
Seagen Inc.	6	$2,150
Johnson & Johnson	28	$480
Daiichi Sankyo Inc.	22	$478
Eisai Inc.	25	$423
Regeneron Healthcare Solutions, Inc.	18	$366
AstraZeneca	20	$343
Incyte Corporation	14	$321
GSK	16	$319
Novartis	12	$249
Exelixis Inc.	10	$204
Amgen	11	$176
Baxter Healthcare	5	$175
Sanofi	8	$151
Pfizer	4	$131
Sobi, Inc	7	$126
Takeda Pharmaceuticals U.S.A., Inc.	4	$86
Pharmaessentia USA Corporation	4	$71
Hologic Sales And Service, LLC	1	$69
Tempus AI, Inc	4	$63
Lilly USA, LLC	3	$52
Immunogen, Inc.	3	$50
Dendreon Pharmaceuticals LLC	2	$48
Servier Pharmaceuticals LLC	3	$47
Genentech USA, Inc.	3	$47
AbbVie	2	$38
Stemline Therapeutics Inc.	2	$37
Blueprint Medicines Corporation	2	$37
Genmab U.S., Inc.	2	$36
Pharmacosmos Therapeutics Inc.	2	$33
Mirati Therapeutics, Inc.	2	$32
EMD Serono, Inc.	2	$31
Taiho Oncology, Inc.	2	$30
Apellis Pharmaceuticals, Inc.	2	$30
Myovant Sciences Inc.	2	$25
Novo Nordisk	1	$22
Progenics Pharmaceuticals, Inc.	1	$21
E.r. Squibb & Sons, L.L.C.	1	$17
Clovis Oncology, Inc.	1	$17
Caris MPI, Inc.	1	$17
AVEO Pharmaceuticals, Inc.	1	$16
Rigel Pharmaceuticals, Inc.	1	$16
Sumitomo Pharma America, Inc.	1	$15
Puma Biotechnology, Inc.	1	$15
Myriad Genetic Laboratories, Inc.	1	$14
ADC Therapeutics America, Inc.	1	$14
Morphosys, US Inc.	1	$13
Karyopharm Therapeutics Inc.	1	$12
Coherus Oncology, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$528,842 in reported general payments places this provider in the 85th percentile of 27 gynecologic oncology providers in Alabama.

See all gynecologic oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$89,616

Medicare patients

133

Services billed

515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Megestrol Acetate	23	$992
Ondansetron Hcl	41	$495
Imiquimod	13	$418
Letrozole	17	$379
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	27	$201
Potassium Chloride	12	$154
Promethazine Hcl	11	$81

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Mobile

Jennifer PierceMobile$4K
Sagar ChokshiMobile$1K
Kenneth BrewingtonMobile$16
Rebecca ArendBirmingham$10M
Charles LeathBirmingham$1.8M
Michael ToboniBirmingham$1.1M
Warner HuhBirmingham$80K
Haller SmithBirmingham$53K
Margaret LiangBirmingham$15K
Groesbeck ParhamBirmingham$11K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →